Elsevier

Clinical Therapeutics

Volume 23, Issue 2, February 2001, Pages 213-227
Clinical Therapeutics

Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee

https://doi.org/10.1016/S0149-2918(01)80004-7Get rights and content

Abstract

Objective: The purpose of this study was to compare the efficacy and tolerability of a celecoxib 200 mg QD regimen with a 100 mg BID regimen in patients with osteoarthritis (OA) of the knee.

Methods: Patients enrolled in this prospective, double-blind, placebo-controlled, parallel-group, multicenter study were randomly assigned to receive celecoxib 100 mg BID, celecoxib 200 mg QD, or placebo for 6 weeks. Assessments of OA severity (Patient's and Physician's Global Assessments of Arthritis, Patient's Assessment of Arthritis Pain—Visual Analog Scale, Lequesne Osteoarthritis Severity Index, and the Western Ontario and McMaster Universities Osteoarthritis Index) were performed at baseline and at week 2 and/or 6. Patients who discontinued treatment underwent assessments at the time of withdrawal from the study.

Results: Of the 718 patients enrolled, 243 received celecoxib 100 mg BID, 231 received celecoxib 200 mg QD, and 244 received placebo. For all measures of efficacy, at all assessments, improvements from baseline in both celecoxib groups were superior to that seen in the placebo group (P < 0.05). No significant differences in efficacy between the celecoxib groups were observed. The overall incidence of adverse events was similar in the 2 celecoxib treatment groups.

Conclusions: Dosing regimens of celecoxib 200 mg QD and 100 mg BID are equally effective and well tolerated in patients with OA of the knee. The availability of 2 effective regimens provides patients and physicians with increased flexibility in the selection of an appropriate dosing regimen for celecoxib therapy.

References (30)

  • G Singh et al.

    Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study

    Arch Intern Med

    (1996)
  • S Kawai

    Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: A clinical consideration

    Inflamm Res

    (1998)
  • J Fries

    Toward an understanding of NSAID-related adverse events: The contribution of longitudinal data

    Scand J Rheumatol Suppl.

    (1996)
  • BF McAdam et al.

    Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2

    Proc Natl Acad Sci USA

    (1999)
  • LJ Crofford

    COX-1 and COX-2 tissue expression: Implications and predictions

    J Rheumatol

    (1997)
  • Cited by (63)

    • Celecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after intra-articular injection

      2016, Journal of Controlled Release
      Citation Excerpt :

      Since serine proteases are present in synovial fluid and a key component of the inflammatory response, drug release from a PEA based DDS is potentially reactive to the disease process in inflammation related conditions such as OA [12,13]. A candidate anti-inflammatory drug to incorporate into PEA microspheres is the COX-2 inhibitor celecoxib, which is an anti-inflammatory drug that has been shown to be an effective analgesic for OA related pain [14]. Celecoxib, when administered systemically, has been reported to raise the risk for cardiovascular events, however incorporating the drug in a PEA based DDS for intra-articular administration can circumvent these side effects [15].

    • Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: A meta-analysis of randomized placebo-controlled trials

      2010, Osteoarthritis and Cartilage
      Citation Excerpt :

      The results of the article selection process are reported in Fig. 1. From the 343 articles identified, 33 articles were included14–46. Flare design was used in 27/33 (82%) studies.

    • COX-2 Selective Inhibitors in the Treatment of Osteoarthritis

      2008, Seminars in Arthritis and Rheumatism
      Citation Excerpt :

      Similar results were found when the American Pain Society Pain Measure Questionnaire was used as the outcome measure (14). Other studies in patients with OA of the knee found that celecoxib 100 mg twice daily and diclofenac 50 mg thrice daily had similar efficacy (15) and that celecoxib efficacy was not significantly different whether dosed at 100 mg twice daily or 200 mg once daily (both doses were superior to placebo) (16). Hence, the usual clinical practice is to begin therapy with 200 mg once daily; indeed, this is the most frequently prescribed dose in patients with OA (17).

    • Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials

      2007, European Journal of Pain
      Citation Excerpt :

      Subgroup analyses showed a reduction of heterogeneity to non-significance (p ⩾ 0.3) for pain data in both subgroups (Q-value 13.8 and 10.8 for biased and unbiased trials, respectively). Maximum efficacy for the subgroup of 14 trials (Weaver et al., 1995; Makarowski et al., 1996; Simon et al., 1998; Bensen et al., 1999; Zhao et al., 1999a; Ehrich et al., 2001; McKenna et al., 2001a,b; Williams et al., 2001; Gottesdiener et al., 2002; Case et al., 2003; Gibofsky et al., 2003; Kivitz et al., 2004; Detrembleur et al., 2005) which used this responder criterion was significantly higher (p < 0.001) at 11.8 mm [95% CI 10.5–13.1] on VAS, than for the 12 other trials (Lee et al., 1985; Williams et al., 1989; Dore et al., 1995; Schnitzer et al., 1995; Fleischmann et al., 1997; Lund et al., 1998; Scott et al., 2000; Uzun et al., 2001; Kivitz et al., 2002; Tannenbaum et al., 2004; Lehmann et al., 2005; Sheldon et al., 2005) where maximum efficacy was 7.9 mm [95% CI 6.9 to 8.9] on VAS. This difference persisted over time and was highly significant at secondary outcome measurements too (p < 0.001).

    View all citing articles on Scopus
    View full text